TMAO and Gut Microbial-Derived Metabolites TML and γBB Are Not Associated with Thrombotic Risk in Patients with Venous Thromboembolism

Canyelles, Marina; Plaza, Melania; Rotllan, Noemí; Llobet, Dolors; Julve, Josep; Mojal, Sergi; Diaz-Ricart, Maribel; Soria, José Manuel; Escolà-Gil, Joan Carles; Tondo, Mireia; Blanco-Vaca, Francisco; Souto, Joan Carles

doi:10.3390/jcm11051425

Open AccessArticle

TMAO and Gut Microbial-Derived Metabolites TML and γBB Are Not Associated with Thrombotic Risk in Patients with Venous Thromboembolism

by

Marina Canyelles

^1,2,3,4

,

Melania Plaza

^1,5,

Noemí Rotllan

^1,3

,

Dolors Llobet

^1,5,

Josep Julve

^1,3

,

Sergi Mojal

^1,5,

Maribel Diaz-Ricart

⁶,

José Manuel Soria

^1,7,

Joan Carles Escolà-Gil

^1,3

,

Mireia Tondo

^2,3,*,†

,

Francisco Blanco-Vaca

^2,3,4,*,†

and

Joan Carles Souto

^1,5,†

¹

Institut de Recerca de l’Hospital Santa Creu i Sant Pau, Institut d’Investigacions Biomèdiques IIB Sant Pau, 08041 Barcelona, Spain

²

Department of Clinical Biochemistry, Hospital de la Santa Creu i Sant Pau, IIB Sant Pau, 08041 Barcelona, Spain

³

CIBER de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), 28029 Madrid, Spain

⁴

Department de Bioquímica i Biologia Molecular, Universitat Autònoma de Barcelona, 08041 Barcelona, Spain

⁵

Unit of Thrombosis and Hemostasis, Hospital de la Santa Creu i Sant Pau, 08041 Barcelona, Spain

⁶

Hematopathology, Department of Pathology, Centre de Diagnostic Biomedic (CDB), Hospital Clinic de Barcelona, Institut d’Investigacions Biomediques August Pi i Sunyer (IDIBAPS), Universitat de Barcelona, 08007 Barcelona, Spain

⁷

Genomics of Complex Diseases Group, Research Institute of Hospital de la Santa Creu i Sant Pau, IIB Sant Pau, 08041 Barcelona, Spain

^*

Authors to whom correspondence should be addressed.

^†

These authors contributed equally to this work.

J. Clin. Med. 2022, 11(5), 1425; https://doi.org/10.3390/jcm11051425

Submission received: 28 January 2022 / Revised: 23 February 2022 / Accepted: 3 March 2022 / Published: 4 March 2022

(This article belongs to the Special Issue Biomarkers for Cardiovascular Risk)

Download

Browse Figure

Versions Notes

Abstract

Background: The present work evaluates the association between circulating concentrations of Trimethylamine-N-oxide (TMAO), gamma butyrobetaine (γBB), and trimetyllisine (TML) in controls and patients with venous thromboembolism (VTE) with coagulation parameters. Methods: The study involved 54 VTE patients and 57 controls. Platelet function, platelet hyperreactivity, platelet adhesiveness, thrombosis-associated parameters, and thrombin generation parameters were studied. Plasma TMAO, γBB, and TML determination was performed using an ultra-high-performance liquid chromatography system coupled with mass spectrometry. Results: No differences were found for TMAO, γBB, or TML concentrations between controls and VTE patients. In thrombin generation tests, TMAO, γBB, and TML showed a positive correlation with lag time and time to peak. TMAO, γBB, and TML negatively correlated with peak height. No significant differences were observed regarding TMAO, γBB, and TML concentrations between the two blood withdrawals, nor when the control and VTE patients were analyzed separately. No correlation was observed between these gut metabolites and platelet function parameters. Conclusions: No differences were found regarding TMAO, γBB, and TML concentrations between the control and VTE groups. Some correlations were found; however, they were mild or went in the opposite direction of what would be expected if TMAO and its derivatives were related to VTE risk.

Keywords: trimethylamine N-oxide; TMAO; γBB; TML; liquid chromatography–mass spectrometry; venous thromboembolism

Share and Cite

MDPI and ACS Style

Canyelles, M.; Plaza, M.; Rotllan, N.; Llobet, D.; Julve, J.; Mojal, S.; Diaz-Ricart, M.; Soria, J.M.; Escolà-Gil, J.C.; Tondo, M.; et al. TMAO and Gut Microbial-Derived Metabolites TML and γBB Are Not Associated with Thrombotic Risk in Patients with Venous Thromboembolism. J. Clin. Med. 2022, 11, 1425. https://doi.org/10.3390/jcm11051425

AMA Style

Canyelles M, Plaza M, Rotllan N, Llobet D, Julve J, Mojal S, Diaz-Ricart M, Soria JM, Escolà-Gil JC, Tondo M, et al. TMAO and Gut Microbial-Derived Metabolites TML and γBB Are Not Associated with Thrombotic Risk in Patients with Venous Thromboembolism. Journal of Clinical Medicine. 2022; 11(5):1425. https://doi.org/10.3390/jcm11051425

Chicago/Turabian Style

Canyelles, Marina, Melania Plaza, Noemí Rotllan, Dolors Llobet, Josep Julve, Sergi Mojal, Maribel Diaz-Ricart, José Manuel Soria, Joan Carles Escolà-Gil, Mireia Tondo, and et al. 2022. "TMAO and Gut Microbial-Derived Metabolites TML and γBB Are Not Associated with Thrombotic Risk in Patients with Venous Thromboembolism" Journal of Clinical Medicine 11, no. 5: 1425. https://doi.org/10.3390/jcm11051425

APA Style

Canyelles, M., Plaza, M., Rotllan, N., Llobet, D., Julve, J., Mojal, S., Diaz-Ricart, M., Soria, J. M., Escolà-Gil, J. C., Tondo, M., Blanco-Vaca, F., & Souto, J. C. (2022). TMAO and Gut Microbial-Derived Metabolites TML and γBB Are Not Associated with Thrombotic Risk in Patients with Venous Thromboembolism. Journal of Clinical Medicine, 11(5), 1425. https://doi.org/10.3390/jcm11051425

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Menu

TMAO and Gut Microbial-Derived Metabolites TML and γBB Are Not Associated with Thrombotic Risk in Patients with Venous Thromboembolism

Abstract

Share and Cite

Article Metrics

Article Access Statistics

Further Information

Guidelines

MDPI Initiatives

Follow MDPI